# LanzaTech Global, Inc.: financial statements, quarterly

LNZA · Nasdaq · CIK 1843724 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lnza.md) · [Financials](/companies/lnza/financials.md) · [Filings](/companies/lnza/filings.md) · [Insiders](/companies/lnza/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lnza/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [19.6](/filings/0001628280-24-046524.md) | [20.5 d](/filings/0001628280-25-017874.md) | [10.2](/filings/0001628280-25-026381.md) | [17.4](/filings/0001628280-25-040832.md) | [9.9](/filings/0001628280-25-053255.md) | [12.0 d](/filings/0001628280-26-022505.md) | [9.5](/filings/0001628280-26-034773.md) | [9.1](/filings/0001628280-26-056933.md) | [9.3](/filings/0001628280-25-053255.md) | [28.0 d](/filings/0001628280-26-022505.md) | [12.0](/filings/0001628280-26-034773.md) | [9.0](/filings/0001628280-26-056933.md) |
| Research and development | $m | [16.6](/filings/0001628280-24-046524.md) | [16.3 d](/filings/0001628280-25-017874.md) | [17.1](/filings/0001628280-25-026381.md) | [21.5](/filings/0001628280-25-040832.md) | [22.0](/filings/0001628280-25-053255.md) | [16.5 d](/filings/0001628280-26-022505.md) | [16.5](/filings/0001628280-26-034773.md) | [14.9](/filings/0001628280-26-056933.md) | [10.3](/filings/0001628280-25-053255.md) | [11.5 d](/filings/0001628280-26-022505.md) | [4.0](/filings/0001628280-26-034773.md) | [2.0](/filings/0001628280-26-056933.md) |
| Selling, general and administrative | $m | [11.8](/filings/0001628280-24-046524.md) | [9.3 d](/filings/0001628280-25-017874.md) | [11.0](/filings/0001628280-25-026381.md) | [11.7](/filings/0001628280-25-040832.md) | [11.5](/filings/0001628280-25-053255.md) | [15.7 d](/filings/0001628280-26-022505.md) | [15.7](/filings/0001628280-26-034773.md) | [19.1](/filings/0001628280-26-056933.md) | [6.7](/filings/0001628280-25-053255.md) | [5.5 d](/filings/0001628280-26-022505.md) | [8.6](/filings/0001628280-26-034773.md) | [8.8](/filings/0001628280-26-056933.md) |
| Operating income | $m | [(24.6)](/filings/0001628280-24-046524.md) | [(18.6) d](/filings/0001628280-25-017874.md) | [(26.2)](/filings/0001628280-25-026381.md) | [(22.8)](/filings/0001628280-25-040832.md) | [(33.0)](/filings/0001628280-25-053255.md) | [(27.0) d](/filings/0001628280-26-022505.md) | [(31.1)](/filings/0001628280-26-034773.md) | [(32.2)](/filings/0001628280-26-056933.md) | [(15.7)](/filings/0001628280-25-053255.md) | [(0.2) d](/filings/0001628280-26-022505.md) | [(9.8)](/filings/0001628280-26-034773.md) | [(9.9)](/filings/0001628280-26-056933.md) |
| Income tax | $m | [0.0](/filings/0001628280-23-038368.md) | [0.0 d](/filings/0001628280-25-017874.md) | [0.0](/filings/0001628280-25-026381.md) | [0.0](/filings/0001628280-25-040832.md) | [0.0](/filings/0001628280-25-053255.md) | [0.0 d](/filings/0001628280-26-022505.md) | [0.0](/filings/0001628280-26-034773.md) | [0.0](/filings/0001628280-26-056933.md) | [0.0](/filings/0001628280-25-053255.md) | [0.0 d](/filings/0001628280-26-022505.md) | [0.0](/filings/0001628280-26-034773.md) | [0.0](/filings/0001628280-26-056933.md) |
| Net income | $m | [(25.3)](/filings/0001628280-24-046524.md) | [(18.7) d](/filings/0001628280-25-017874.md) | [(25.5)](/filings/0001628280-25-053255.md) | [(27.8)](/filings/0001628280-25-053255.md) | [(57.4)](/filings/0001628280-25-053255.md) | [(27.0) d](/filings/0001628280-26-022505.md) | [(19.2)](/filings/0001628280-26-056933.md) | [(32.5)](/filings/0001628280-26-056933.md) | [2.9](/filings/0001628280-25-053255.md) | [(0.1) d](/filings/0001628280-26-022505.md) | [(14.7)](/filings/0001628280-26-056933.md) | [184](/filings/0001628280-26-056933.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001628280-24-046524.md) | not reported | [(0.13)](/filings/0001628280-25-026381.md) | [(0.14)](/filings/0001628280-25-040832.md) | [(29.04)](/filings/0001628280-25-053255.md) | not reported | [(9.79)](/filings/0001628280-26-034773.md) | [(14.90)](/filings/0001628280-26-056933.md) | [0.99](/filings/0001628280-25-053255.md) | not reported | [(1.77)](/filings/0001628280-26-034773.md) | [15.81](/filings/0001628280-26-056933.md) |
| Basic EPS | $ per share | [(0.13)](/filings/0001628280-24-046524.md) | not reported | [(0.13)](/filings/0001628280-25-026381.md) | [(0.14)](/filings/0001628280-25-040832.md) | [(29.04)](/filings/0001628280-25-053255.md) | not reported | [(9.79)](/filings/0001628280-26-034773.md) | [(14.90)](/filings/0001628280-26-056933.md) | [1.14](/filings/0001628280-25-053255.md) | not reported | [(1.77)](/filings/0001628280-26-034773.md) | [15.81](/filings/0001628280-26-056933.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [91.4](/filings/0001628280-23-038368.md) | [75.6](/filings/0001628280-25-017874.md) | [56.7](/filings/0001628280-24-021946.md) | [62.2](/filings/0001628280-24-035831.md) | [58.7](/filings/0001628280-24-046524.md) | [43.5](/filings/0001628280-26-022505.md) | [13.8](/filings/0001628280-25-026381.md) | [37.4](/filings/0001628280-25-040832.md) | [19.6](/filings/0001628280-25-053255.md) | [13.2](/filings/0001628280-26-056933.md) | [19.9](/filings/0001628280-26-034773.md) | [45.0](/filings/0001628280-26-056933.md) |
| Current assets | $m | [177](/filings/0001628280-23-038368.md) | [173](/filings/0001628280-25-017874.md) | [147](/filings/0001628280-24-021946.md) | [125](/filings/0001628280-24-035831.md) | [137](/filings/0001628280-24-046524.md) | [99.3](/filings/0001628280-26-022505.md) | [57.7](/filings/0001628280-25-026381.md) | [66.2](/filings/0001628280-25-040832.md) | [50.6](/filings/0001628280-25-053255.md) | [39.7](/filings/0001628280-26-056933.md) | [48.0](/filings/0001628280-26-034773.md) | [69.2](/filings/0001628280-26-056933.md) |
| Total assets | $m | [246](/filings/0001628280-23-038368.md) | [242](/filings/0001628280-25-017874.md) | [214](/filings/0001628280-24-021946.md) | [212](/filings/0001628280-24-035831.md) | [216](/filings/0001628280-24-046524.md) | [175](/filings/0001628280-26-022505.md) | [126](/filings/0001628280-25-026381.md) | [116](/filings/0001628280-25-040832.md) | [99.3](/filings/0001628280-25-053255.md) | [100](/filings/0001628280-26-056933.md) | [105](/filings/0001628280-26-034773.md) | [323](/filings/0001628280-26-056933.md) |
| Current liabilities | $m | [33.7](/filings/0001628280-23-038368.md) | [27.8](/filings/0001628280-25-017874.md) | [21.3](/filings/0001628280-24-021946.md) | [28.4](/filings/0001628280-24-035831.md) | [46.9](/filings/0001628280-24-046524.md) | [30.4](/filings/0001628280-26-022505.md) | [26.5](/filings/0001628280-25-026381.md) | [55.8](/filings/0001628280-25-040832.md) | [24.8](/filings/0001628280-25-053255.md) | [27.7](/filings/0001628280-26-056933.md) | [24.4](/filings/0001628280-26-034773.md) | [27.9](/filings/0001628280-26-056933.md) |
| Total liabilities | $m | [118](/filings/0001628280-23-038368.md) | [127](/filings/0001628280-25-017874.md) | [123](/filings/0001628280-24-021946.md) | [144](/filings/0001628280-24-035831.md) | [203](/filings/0001628280-24-046524.md) | [161](/filings/0001628280-26-022505.md) | [127](/filings/0001628280-25-026381.md) | [128](/filings/0001628280-25-040832.md) | [91.1](/filings/0001628280-25-053255.md) | [90.9](/filings/0001628280-26-056933.md) | [57.2](/filings/0001628280-26-034773.md) | [62.1](/filings/0001628280-26-056933.md) |
| Long-term debt | $m | [23.4](/filings/0001628280-23-038368.md) | [25.2](/filings/0001628280-24-035831.md) | [15.5](/filings/0001628280-24-021946.md) | [9.3](/filings/0001628280-24-035831.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [128](/filings/0001628280-24-046524.md) | [114](/filings/0001628280-26-022505.md) | [91.8](/filings/0001628280-25-053255.md) | [67.5](/filings/0001628280-25-053255.md) | [13.6](/filings/0001628280-25-053255.md) | [13.4](/filings/0001628280-26-056933.md) | [(1.2)](/filings/0001628280-26-056933.md) | [(25.2)](/filings/0001628280-26-056933.md) | [(5.0)](/filings/0001628280-25-053255.md) | [(3.9)](/filings/0001628280-26-056933.md) | [48.1](/filings/0001628280-26-056933.md) | [261](/filings/0001628280-26-056933.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(22.4) d](/filings/0001628280-24-046524.md) | [(15.7) d](/filings/0001628280-25-017874.md) | [(28.3)](/filings/0001628280-25-026381.md) | [(14.7) d](/filings/0001628280-25-040832.md) | [(26.4) d](/filings/0001628280-25-053255.md) | [(19.7) d](/filings/0001628280-26-022505.md) | [(21.1)](/filings/0001628280-26-034773.md) | [(21.7) d](/filings/0001628280-26-056933.md) | [(15.9) d](/filings/0001628280-25-053255.md) | [(6.2) d](/filings/0001628280-26-022505.md) | [(9.3)](/filings/0001628280-26-034773.md) | [(1.4) d](/filings/0001628280-26-056933.md) |
| Capital expenditure | $m | [1.8 d](/filings/0001628280-24-046524.md) | [1.4 d](/filings/0001628280-25-017874.md) | [1.5](/filings/0001628280-25-026381.md) | [1.8 d](/filings/0001628280-25-040832.md) | [0.3 d](/filings/0001628280-25-053255.md) | [1.8 d](/filings/0001628280-26-022505.md) | [0.7](/filings/0001628280-26-034773.md) | [0.2 d](/filings/0001628280-26-056933.md) | [0.2 d](/filings/0001628280-25-053255.md) | [0.2 d](/filings/0001628280-26-022505.md) | [0.1](/filings/0001628280-26-034773.md) | [0.7 d](/filings/0001628280-26-056933.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.2](/filings/0001628280-23-038368.md) | [117](/filings/0001628280-24-021946.md) | [196](/filings/0001628280-24-035831.md) | [196](/filings/0001628280-24-046524.md) | [197](/filings/0001628280-25-026381.md) | [198](/filings/0001628280-25-040832.md) | [2.0](/filings/0001628280-25-053255.md) | [2.0](/filings/0001628280-26-034773.md) | [2.2](/filings/0001628280-26-056933.md) | [2.7](/filings/0001628280-25-053255.md) | [8.3](/filings/0001628280-26-034773.md) | [11.7](/filings/0001628280-26-056933.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,089,163 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001628280-26-056933.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.